Compliance to Artesunate-Amodiaquine Therapy for Uncomplicated Malaria in Rural Ghana
NCT ID: NCT00873938
Last Updated: 2010-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
411 participants
OBSERVATIONAL
2005-10-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study would assess compliance to Artesunate-Amodiaquine therapy. It would also assess the effect of compliance to artesunate-amodiaquine therapy on clinical and parasitological cure rates. This study targeting age groups above ten years, would complement a child artesunate -amodiaquine efficacy study being undertaken by the same investigators in children ten years and below at Kintampo District at the same time. The funding for the child study has been approved by the Gates Malaria Partnership. Findings from both studies, involving all age groups would be made available to the National Malaria Control Programme and other stakeholders as practical information that may be beneficial to implementing policy change process from antimalarial monotherapy to a combination therapy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
• To determine compliance to artesunate-amodiaquine therapy among patients diagnosed with acute uncomplicated malaria in the Kintampo District Hospital.
Secondary objectives:
1. To determine patients compliance to each of the two drugs (artesunate or amodiaquine )
2. To determine reasons for differential compliance to either of the two drugs (artesunate or amodiaquine).
3. To determine patients perception and acceptance of artesunate-amodiaquine therapy for acute uncomplicated malaria.
4. To determine the effect of compliance of artesunate-amodiaquine therapy on clinical and parasitological improvement in acute uncomplicated malaria.
Study design: The study will be a pragmatic randomized control trial. Patients will be recruited based on an inclusion criteria stated below. Baseline clinical symptoms of malaria and presence of malaria parasite (Plasmodium falciparum) in the blood of eligible patients reporting sick at the health facility would be determined. Study patients would be randomized into one of two groups, intervention and control groups.
Intervention:
The intervention refers to supervisory home visits by a trained community volunteer to ensure that paticipants comply to treatment during the artesunate-amodiaquine therapy. Supervisory home visits by a trained community volunteer form a major component of the Community Health Planning and Services programme being implemented by the Ghana Health Service. The intervention group would be supervised during artesunate-amodiaquine therapy and the control group would not be supervised during artesunate-amodiaquine therapy. The primary and secondary outcome measures below will be determined and compared among the intervention and control group
Primary outcome measure:
The main outcome is compliance to artesunate-amodiaquine combination therapy. It is defined as no artesunate or amodiaquine left on the fourth day after start of treatment of a malaria episode. This would be assessed by the investigators direct observation of the blister package of artesunate-Amodiaquine tablets.
Secondary outcome measures:
* Reasons for non-compliance would be determined by response of study participants. Care-takers of children below 18 years will answer on behalf of their children with the child's assent.
* Participants' perception and acceptance of supervision: It would be assessed by responses given by study participants in an indepth interview.
* Parasite clearance rates on day 14 and 28 i.e. the proportion of study participants in each group with P. falciparum parasiteamia at day 14 and 28 determined by blood smear microscopy.
* Clinical cure rates by days 14 and 28 i.e. the proportion of study participants in each group with symptoms of malaria on days 14 and 28 determined by a structured questionnaire at these times.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1-supervised
No interventions assigned to this group
2 -unsupervised
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed as having Plasmodium falciparum uncomplicated malaria.
* Axillary temperature ≥37.5oC but less than 40 oC or history of fever in preceding 24 hr.
* Ability to tolerate oral therapy.
* Patient who live and can be located in the Kintampo District.
* Consent of patient and/or care giver (in the case of children)
Exclusion Criteria
* Children ten years and below (to be catered for in the child antimalarial efficacy studies mentioned above).
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
London School of Hygiene and Tropical Medicine
OTHER
Kintampo Health Research Centre, Ghana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kintampo Health Research Centre
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seth Owusu-Agyei, PhD
Role: PRINCIPAL_INVESTIGATOR
Kintampo Health Research Centre, Ghana
Kwaku P Asante, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Kintampo Health Research Centre, Ghana
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kintampo Health Research Centre
Brong Ahafo Region, Kintampo, Ghana
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Institutional Website, Kintampo Health Research Centre
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004/GD/70
Identifier Type: -
Identifier Source: org_study_id